Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency.

abstract：:Arterial and venous thromboses are major contributors to coagulation-associated morbidity and mortality. Greater understanding of mechanisms leading to thrombus formation and stability is expected to lead to improved treatment strategies. Factor XIII (FXIII) is a transglutaminase found in plasma and platelets. During ...

journal_title：Seminars in thrombosis and hemostasis

authors： Byrnes JR,Wolberg AS

更新日期：2016-06-01 00:00:00

abstract：:Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

journal_title：Seminars in thrombosis and hemostasis

authors： Schulze H,Shivdasani RA

更新日期：2004-08-01 00:00:00

abstract：:While case fatality rates in ischemic stroke tend to decline, the total number of strokes is expected to increase further in the future because of more people reaching a greater age. Acute ischemic stroke, usually caused by chronic arterial hypertension, in most cases is induced either by a sudden loss of perfusion pr...

journal_title：Seminars in thrombosis and hemostasis

authors： Huber M,Heiss WD

更新日期：1996-01-01 00:00:00

abstract：:Obtaining a personal history of bleeding is a critical component to the diagnosis of von Willebrand disease (VWD). The collection of this information can be challenging for physicians, however, as the reporting and interpretation of bleeding symptoms is subjective. The need for more precise quantification of bleeding ...

journal_title：Seminars in thrombosis and hemostasis

authors： Bowman ML,James PD

更新日期：2017-07-01 00:00:00

abstract：:Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, an...

journal_title：Seminars in thrombosis and hemostasis

authors： Duga S,Salomon O

更新日期：2009-06-01 00:00:00

abstract：:CD34 (+) progenitor cells are a promising source of regeneration in atherosclerosis or ischemic heart disease. However, as recently published, CD34(+) progenitor cells have the potential to differentiate not only into endothelial cells but also into foam cells upon interaction with platelets. The mechanism of platelet...

journal_title：Seminars in thrombosis and hemostasis

authors： Seizer P,Schiemann S,Merz T,Daub K,Bigalke B,Stellos K,Müller I,Stöckle C,Müller K,Gawaz M,May AE

更新日期：2010-03-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:Anti-factor Xa methods have been generally accepted for the monitoring of heparin treatment mainly due to their sensitivity to LMWH and excellent performance on automated equipment. When such equipment is not available, as in small laboratories or on the night shift, there is a need for a simple manual method. In the ...

journal_title：Seminars in thrombosis and hemostasis

authors： Friberger P,Krig E,Eriksson-Skoog L,Svensson S,Isacson C

更新日期：1993-01-01 00:00:00

abstract：:A diagnosis of hemophilia A or hemophilia B begins with clinical assessment of the patient and is facilitated by laboratory testing. The influence of the latter on a diagnosis of hemophilia A or hemophilia B is clear-a diagnosis cannot be made without laboratory confirmation of a deficiency of factor FVIII (FVIII) or ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Meijer P,Jennings I,Sioufi J,Bonar RA,Kitchen DP,Kershaw G,Lippi G

更新日期：2013-10-01 00:00:00

abstract：:Clotting activation occurs frequently in cancer. Tissue factor (TF), the most potent initiator of coagulation, is expressed aberrantly in many types of malignancy and is involved not only in tumor-associated hypercoagulability but also in promoting tumor angiogenesis and metastasis via coagulation-dependent and coagul...

journal_title：Seminars in thrombosis and hemostasis

authors： Amirkhosravi A,Meyer T,Amaya M,Davila M,Mousa SA,Robson T,Francis JL

更新日期：2007-10-01 00:00:00

abstract：:Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders, that may be controlled by proper administration of adequate prophylaxis with factor VIII (FVIII), and factor IX (FIX) concentrates, respectively, to prevent joint damage due to recurrent bleeding. However, approximately 30% of patie...

journal_title：Seminars in thrombosis and hemostasis

authors： Barg AA,Livnat T,Kenet G

更新日期：2018-09-01 00:00:00

abstract：:With the continued accumulation of clinical and animal studies, it is becoming abundantly clear that the protein C anticoagulant pathway plays a critical role in the regulation of coagulation. Investigations also indicate that this pathway is intimately involved in the interaction of the coagulation and inflammatory s...

journal_title：Seminars in thrombosis and hemostasis

authors： Esmon NL,Esmon CT

更新日期：1988-04-01 00:00:00

abstract：:Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the...

journal_title：Seminars in thrombosis and hemostasis

authors： Römisch J,Bonik K,Müller HG

更新日期：1998-01-01 00:00:00

abstract：:Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

journal_title：Seminars in thrombosis and hemostasis

authors： Danese E,Montagnana M,Lippi G

更新日期：2016-09-01 00:00:00

abstract：:External Quality Control of Diagnostic Assays and Tests (ECAT) surveys on thrombin generation rests (TGTs) have identified that various tests show a more than 30-fold difference in time to peak (TTP). The survey included pooled normal plasmas, microparticle (MP)-depleted plasmas, and factor (F)XII-deficient patient pl...

journal_title：Seminars in thrombosis and hemostasis

authors： Kluft C,Meijer P

更新日期：2010-10-01 00:00:00

abstract：:Until recently, thrombocytoses in childhood were considered to be rare. The literature on this subject is scarce and contradictory. When thrombocytosis is defined as a platelet count of more than 500 x 10(9)/L (500 000/mm3 or 500 000/microL), the occurrence in routine examinations at pediatric hospitals can be estimat...

journal_title：Seminars in thrombosis and hemostasis

authors： Sutor AH

更新日期：1995-01-01 00:00:00

abstract：:There have been no reports on acute pulmonary embolism (APE) after earthquakes. Our aim was to clarify the actual the occurrence of APE following the 2004 Mid Niigata Prefecture earthquake in Japan, and to assess the risk factors for APE after the event. We sent questionnaires to 122 hospitals in the Niigata Prefectur...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuma M,Nakamura M,Hanzawa K,Kobayashi T,Kuroiwa M,Nakanishi N,Miyahara Y,Tanabe N,Yamada N,Kuriyama T,Kunieda T,Sugimoto T,Nakano T,Shirato K

更新日期：2006-11-01 00:00:00

abstract：:Bleeding can be a serious complication of surgery, and topical thrombin is widely used as an adjunct to hemostasis in diverse surgical settings. The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation s...

journal_title：Seminars in thrombosis and hemostasis

authors： Bishop PD,Lewis KB,Schultz J,Walker KM

更新日期：2006-04-01 00:00:00

abstract：:Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

journal_title：Seminars in thrombosis and hemostasis

authors： Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

更新日期：2020-06-01 00:00:00

abstract：:A new in vitro system for the detection of platelet dysfunction, PFA-100, has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane. The...

journal_title：Seminars in thrombosis and hemostasis

authors： Kundu SK,Heilmann EJ,Sio R,Garcia C,Davidson RM,Ostgaard RA

更新日期：1995-01-01 00:00:00

abstract：:Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP). The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores a...

journal_title：Seminars in thrombosis and hemostasis

authors： Cattaneo M

更新日期：2005-04-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:The increased prevalence of the laboratory diagnosis of von Willebrand disease (vWD) in women presenting with menorrhagia has raised concerns regarding certain specifics in vWD testing in women, including when vWD testing should be done in relation to menses and whether testing should be done while the patient is not ...

journal_title：Seminars in thrombosis and hemostasis

authors： Kouides PA

更新日期：2006-07-01 00:00:00

abstract：:Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

journal_title：Seminars in thrombosis and hemostasis

authors： Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

更新日期：2020-09-01 00:00:00

abstract：:In the early 1980s, the first external quality assessment schemes (EQAS) regarding parameters of the coagulation laboratory were established in the daily routine of German laboratories. At present, the EQAS performed by INSTAND offers a wide range of global and single parameters of thrombosis and hemostasis. Only the ...

journal_title：Seminars in thrombosis and hemostasis

authors： Spannagl M,Dick A,Reinauer H

更新日期：2007-04-01 00:00:00

abstract：:The polymorphism in the composition and actions of heparin and the parallel complexity of the thrombotic process have led to the design of a cautious, methodical, and pragmatic program of development of the first low molecular heparin fraction presently available in France (CY 216). The main idea was always to present...

journal_title：Seminars in thrombosis and hemostasis

authors： Toulemonde F

更新日期：1989-10-01 00:00:00

abstract：:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among m...

journal_title：Seminars in thrombosis and hemostasis

authors： Splichal JE,Stamm JA,Ornstein DL

更新日期：2003-06-01 00:00:00

abstract：:These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

journal_title：Seminars in thrombosis and hemostasis

authors： Hiebert L,Liu JM

更新日期：1991-01-01 00:00:00

abstract：:Thrombosis development in either arterial or venous system remains a major cause of death and disability worldwide. This poorly controlled in vivo clotting could result in many severe complications including myocardial infarction, venous thromboembolism, stroke, and cerebral venous thrombosis, to name a few. These con...

journal_title：Seminars in thrombosis and hemostasis

authors： Mishra A,Ashraf MZ

更新日期：2020-06-01 00:00:00

abstract：:The delicate biochemistry of coagulation and anticoagulation is greatly affected by deviations from the optimal temperature required for the interactions between various coagulation enzymes, cellular receptors, and intracellular mechanisms. Hyperthermia will lead to a prothrombotic state and, if sufficiently severe su...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2018-10-01 00:00:00